Hydroxyurea and hydroxamic acid derivatives as antitumor drugs

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 213-221

  Saban, Nina ^a   Bujak, Maro ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cancer; Hydroxamic acid derivatives; Hydroxyurea

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ACTINONIN; AZELAIC BISHYDROXAMIC ACID; BATIMASTAT; BB 3103; BL 1521; CARBOPLATIN; CGS 27023A; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; HYDROXYUREA; ITF 2357; KB R 7785; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N BENZYL N HYDROXY 5 PHENYLPENTANAMIDE; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; OXAMFLATIN; PACLITAXEL; PANOBINOSTAT; PRINOMASTAT; PYROXAMIDE; SOLIMASTAT; SUBERIC BISHYDROXAMATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONVULSION; CUTANEOUS T CELL LYMPHOMA; DERMATOMYOSITIS; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; FACE ERYTHEMA; GONADAL DISEASE; HALLUCINATION; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERPIGMENTATION; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG CANCER; MACULOPAPULAR RASH; MELANOMA; MENINGIOMA; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NAIL ATROPHY; NAIL DISEASE; NAUSEA; NONHUMAN; OVARY CARCINOMA; PAPULE; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SEZARY SYNDROME; SHORT SURVEY; SICKLE CELL ANEMIA; SKIN ATROPHY; SKIN ULCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TUMOR CELL; UREMIA; UTERINE CERVIX CARCINOMA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; HYDROXAMIC ACIDS; HYDROXYUREA; NEOPLASMS;

EID: 67349092776     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0991-z     Document Type: Short Survey

References (109)

1. WFC Dresler R Stein 1869 Ueber den Hydroxylharnstoff. Justus Liebigs Ann Chem Pharmacol 150 242 252
2. FS Philips SS Sternberg HS Schwartz AP Cronin JE Sodergren PM Vidal 1967 Hydroxyurea. I. Acute cell death in proliferating tissues in rats Cancer Res 27 61 74
3. HM Rabes G Iseler S Czichos HV Tuczek 1977 Synchronization of hepatocellular DNA synthesis in regenerating rat liver by continious infusion of hydroxyurea Cancer Res 37 1105 1111 (Pubitemid 8088182)
4. F Rosenthal L Wislicki L Kollek 1928 Uber die beziehungen von schwersten blutgiften zu abbauprodukten des eiweisses Klin Wochenschr 7 972 977
5. JW Yarbro BJ Kennedy CP Barnum 1965 Hydroxyurea inhibition of DNA synthesis in ascites tumor Proc Natl Acad Sci US 53 1033 1035
6. CW Young S Hodas 1964 Hydroxyurea inhibitory effect on DNA metabolism Science 146 1172 1174
7. RLP Adams JG Lindsay 1967 Hydroxyurea. Reversal of inhibition and use as a cell-synchronizing agent J Biol Chem 242 1314 1317
8. IH Krakoff NC Brown P Reichard 1968 Inhibition of ribonucleoside diphosphate reductase by hydroxyurea Cancer Res 28 1559 1565
9. Mutschler E, Derendorf H (1995) Drug actions, basic principles and therapeutics aspects. Medpharm Scientific Publishers, Stuttgart
10. S Charache GJ Dover MA Moyer 1987 Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia Blood 69 109
11. S Charache ML Terrin RD Moore GJ Dover FB Barton SV Eckert RP NcMahon DR Bonds 1995 Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia N Engl J Med 332 1317 1322
12. AN Schechter GP Rodgers 1995 Sickle cell anemia: basic research reaches the clinic N Engl J Med 332 1372 1374
13. WY Gao A Cara RC Gallo F Lori 1993 Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication Proc Natl Acad Sci USA 90 8925 8928
14. S Cortelazzo G Finazzi M Ruggeri O Vestri M Galli F Rodeghiero T Barbui 1995 Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis New Eng J Med 332 1132 1136
15. M Rosten 1971 Hydroxyurea: a new antimetabolite in the treatment of psoriasis Br J Dermatol 85 177 181
16. PB Donovan ME Kaplan JD Goldberg I Tatarsky Y Najean EB Silberstein WH Knospe J Laszlo K Mack PD Berk LR Wasserman 2006 Treatment of polycythemia vera with hydroxyurea Am J Hematology 17 329 334 (Pubitemid 15201281)
17. S Hannessian S Johnstone 1999 Synthesis of hydroxamic esters via alkoxyaminocarbonylation of β-dicarbonyl compounds J Org Chem 64 5896 5903
18. T Kolasa AO Steward CDW Brooks 1996 Asymetric synthesis of (R)-N-3-butyn-2-yl-N-hydroxyurea, a key intermediate for 5-lipoxygenase inhibitors Tetrahedron: Asymetry 7 729 736 (Pubitemid 26116309)
19. P Nandy EJ Lien VI Avramis 1999 Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (ara-C) and induction of cellular apoptosis Anticancer Res 19 1625 1633 (Pubitemid 29395581)
20. Kleeman A, Engel J, Kutscher B, Reichert D (2001) Pharmaceutical substances, synthesis, patents, applications, 4th edn. Thieme, Stuttgart
21. ML Slater 1973 Effect of reversible inhibition of deoxyribonucleic acid synthesis on the yeast cell cycle J Bacteriol 113 263 270
22. G Lassmann L Thelander A Graslund 1992 EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea Biochem Biophys Res Commun 188 879 887
23. PR Gwilt WG Tracewell 1998 Pharmacokinetics and pharmacodynamics of hydroxyurea Clin Pharmacokinet 34 347 358 (Pubitemid 28192905)
24. J Jiang SJ Jordan DP Barr MR Gunther H Maeda RP Mason 1997 In vivo production of nitric oxide in rats after administration of hydroxyurea Mol Pharmacol 52 1081 1086
25. SB King 2003 The nitric oxide producing reactions of hydroxyurea Curr Med Chem 10 437 452 (Pubitemid 36221573)
26. MJ Burrkitt A Raft 2006 Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders Blood 107 2219 2222
27. CW Young G Schochetman S Hodas ME Balis 1967 Inhibition of DNA synthesis by hydroxyurea: structure-activity relationship Cancer Res 27 535 540
28. HR Elford GL Wampler B van't Riet 1979 New ribonucleotide reductase inhibitors with antineoplastic activity Cancer Res 39 844 851 (Pubitemid 9143275)
29. DA Parrish Z Zou CL Allen CS Day SB King 2005 A convenient method for the synthesis of N-hydroxyureas Tetrahedron Lett 46 8841 8843 (Pubitemid 41665913)
30. A Scozzafava CT Supuran 2003 Hydroxyurea is a carbonic anhydrase inhibitor Bioorg Med Chem 11 2241 2246 (Pubitemid 36457850)
31. H Elford 1968 Effect of hydroxyurea on ribonucleotide reductase Biochem Biophys Res Commun 33 129 135
32. EC Moore 1969 The effect of ferrous ion and dithioerythritol on inhibition by hydroxyurea of ribonucleotide reductase Cancer Res 29 291 295
33. GI Rodriguez JG Kuhn GR Weiss SG Hilsenbeck JR Eckardt A Thurman DA Rinaldi S Hodges DD Von Hoff EK Rowinsky 1998 A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea Blood 91 1533 1541 (Pubitemid 28110316)
34. RC Donehower 1992 An overview of the clinical experience with hydroxyurea Semin Oncol 19 11 19
35. V Gandhi W Plunkett H Kantarjian M Talpaz LE Robertson S O'Brien 1998 Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia J Clin Oncol 16 2321 2331 (Pubitemid 28309023)
36. Kacew S (1989) Drug toxicity and metabolism in pediatrics. CRC Press, Boca Raton
37. F Ravandi-Kashani J Cortes P Cohen M Talpaz S O'Brien A Markowitz H Kantarjian 1999 Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders Leuk Lymphoma 35 109 118 (Pubitemid 29454408)
38. ME Sirieix C Debure N Baudot L Dubertret ME Roux P Morel C Frances S Loubeyres C Beylot D Lambert P Humbert O Gauthier M Dandurand B Guillot L Vaillant G Lorette JM Bonnetblanc C Lok JP Denoeux 1999 Leg ulcers and hydroxyurea Arch Dermatol 135 818 820
39. M Richard F Truchetet J Friedel C Leclech E Heid 1989 Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy J Am Acad Dermatol 21 797 799 (Pubitemid 19251749)
40. A Velez F Lopez-Rubio JC Moreno 1998 Chronic hydroxyurea-induced dermatomyositis-like eruption with severe dermal elastosis Clin Exp Dermatol 23 94 95 (Pubitemid 28308377)
41. CA Gropper PC Don MM Sadjadi 1993 Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera Int J Dermatol 32 731 733 (Pubitemid 23326986)
42. M De Montalembert M Belloy F Bernaudin F Gouraud R Capdeville R Mardini N Philippe JP Jais J Bardakdijan R Ducrocq M Maier-Redelsperger J Elion D Labie R Girot 1997 Three-year follow-up of hxdroxyurea treatment in severely ill children with sickle cell disease J Pediatr Hematol/Oncol 19 313 318 (Pubitemid 27464889)
43. RT Silver SH Woolf R Hehlmann FR Appelbaum J Anderson C Bennett JM Goldman F Guilhot HM Kantarjian AE Lichtin M Talpaz S Tura 1999 An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic Blood 94 1517 1536
44. JM Goldman 1997 Optimizing treatment for chronic myeloid leukemia New Engl J Med 337 270 271 (Pubitemid 27310445)
45. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Quei er W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Wei J, Meier CR, Kremers S, Labedzki., Schmeiser T, Lohrmann H-P, Heimpel P, the German CML-Study Group (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529-1537 (Pubitemid 36986954)
46. MS Piver JJ Barlow V Vongtama L Blumenson 1983 Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study Am J Obstet Gynecol 147 803 808 (Pubitemid 14247609)
47. MM Hreshchyshyn BS Aron RC Boronow EW Franklin 3rd HM Shingleton JA Blessing 1979 Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis Int J Radiat Oncol Biol Phys 5 317 322 (Pubitemid 9155751)
48. UMH Schrell MG Rittig U Koch R Marschalek M Anders 1996 Hydroxyurea for treatment of unresectable meningiomas Lancet 348 888 889 (Pubitemid 26320911)
49. UMH Schrell MG Rittig M Anders F Kiesewetter R Marschalek UH Koch 1997 Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway J Neurosurg 86 845 852 (Pubitemid 27187688)
50. KV Cammack RM Taylor 1972 Advanced neoplasm of head and neck. Treatment with combined radiation and chemotherapy Rocky Mt Med J 69 54 56
51. GJ Richards RG Chambers 1973 Hydroxyurea in the treatment of neoplasm of head and neck Am J Surg 126 513 518
52. DH Hussey P Abrams 1975 Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy Prog Clin Cancer 6 79 86
53. HJ Lerner 1978 Concomitant hydroxyurea and irradiation. Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania Hospital Am J Surg 134 505 550
54. RG Blasberg C Patlack JD Fenstermacher 1975 Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion J Pharmacol Exp Ther 195 73 83
55. DR Walkinshaw XJ Yang 2008 Histone deacetylase inhibitors as novel anticancer therapeutics Curr Oncol 15 237 243
56. ML Rothenberg AR Nelson KR Hande 1999 New drugs on the horizon: matrix metalloproteinase inhibitors Stem Cells 17 237 240
57. U Mahlknecht D Hoelzer 2000 Histone acetylation modifiers in the pathogenesis of malignant disease Mol Med 6 623 644
58. WD Cress E Seto 2000 Histone deacetylases, transcriptional control, and cancer J Cell Physiol 184 1 16 (Pubitemid 30349623)
59. PA Marks RA Rifkind VM Richon R Breslow 2001 Inhibitors of histone deacetylase are potentially effective anticancer agents Clin Cancer Res 7 759 760 (Pubitemid 32708707)
60. RW Johnstone 2002 Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 287 299 (Pubitemid 37361445)
61. M Duvic J Vu 2007 Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T cell lymphoma Expert Opin Investig Drugs 16 1111 1120 (Pubitemid 47074165)
62. AR Nelson B Fingleton ML Rothenberg LM Matrisian 2000 Matrix metalloproteinases: biologic activity and clinical implications J Clin Oncol 18 1135 1149 (Pubitemid 30123793)
63. Avendano C, Menendez JC (2008) Medicinal chemistry of anticancer drugs. Elsevier, Amsterdam
64. JB Cross JS Duca JJ Kaminski VS Madison 2002 The active site of a zinc-dependent metalloproteinase influences the computed pKa of ligands coordinated to the catalytic zinc ion J Am Chem Soc 124 11004 11007
65. I Botos L Scapozza D Zhang LA Liotta EF Meyer 1996 Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding Proc Nat Acad Sci USA 93 2749 2754 (Pubitemid 26116235)
66. Rasmussen HS, Teicher BA (eds) (1999) Antiangiogenic agents in cancer therapy. Humana Press, Totowa
67. PD Brown 1999 Clinical studies with matrix metalloproteinase inhibitors APMIS 107 174 180 (Pubitemid 29133538)
68. S Wojtowicz-Praga J Low J Marshall E Ness R Dickson J Barter M Sale P McCann J Moore A Cole MJ Hawkins 1996 Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer Invest New Drugs 14 193 202 (Pubitemid 26340688)
69. VM Macaulay KJ O'Byrne MP Saunders JP Braybrooke L Long F Gleeson CS Mason AL Harris P Brown DC Talbot 1999 Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions Clin Cancer Res 5 513 520 (Pubitemid 29131959)
70. GJ Beattie JF Smyth 1998 Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites Clin Cancer Res 4 1899 1902 (Pubitemid 28369173)
71. ML Rothenberg AR Nelson KR Hande 1998 New drugs on the horizon: matrix metalloproteinase inhibitors Oncologist 3 271 274 (Pubitemid 28399653)
72. DR Shalinsky J Brekken H Zou CD McDermott P Forsyth D Edwards S Margosiak S Bender G Truitt A Wood NM Varki K Appelt 1999 Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials Ann N Y Acad Sci 878 236 270 (Pubitemid 29353575)
73. PA Marks M Dokmanovic 2005 Histone deacetylase inhibitors: discovery and development as anticancer agents Expert Opin Investig Drugs 14 1497 1511 (Pubitemid 41749195)
74. MS Finnin JR Donigian J Venitz WD Figg 1999 Rational development of histone deacetylase homologue bound to TSA and SAHA Nature 401 188 193 (Pubitemid 29436325)
75. MR Acharya A Sparreboom J Venitz WD Figg 2005 Rational development of histone deacetylase inhibitors as anticancer agents: a review Mol Pharmacol 68 917 932 (Pubitemid 41345783)
76. C Monneret 2005 Histone deacetylase inhibitors Eur J Med Chem 40 1 13 (Pubitemid 40092373)
77. HY Lin CS Chen SP Lin JR Weng CS Chen 2006 Targeting histone deacetylase in cancer therapy Med Res Rev 26 397 413
78. Y Sowa T Orita S Minamikawa K Nakano T Mizuno H Nomura T Sakai 1997 Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites Biochem Biophys Res Commun 241 142 150 (Pubitemid 28033553)
79. T Hirose Y Sowa S Takahashi S Saito C Yasuda N Shindo K Furuichi T Sakai 2003 p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y Oncogene 22 7762 7773 (Pubitemid 37485535)
80. N Takai T Ueda M Nishida K Nasu H Narahara 2008 Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells Int J Mol Med 21 109 115
81. M Quaissi M Quaissi 2006 Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases Biomed Biotechnol 2006 134747 13477
82. R Hoekstra FALM Eskens J Verweij 2001 Matrix metalloproteinase inhibitors: current developments and future perspectives Oncologist 6 415 427 (Pubitemid 33022212)
83. S Zucker J Cao W-T Chen 2000 Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 6642 6650 (Pubitemid 32197703)
84. M-J Lee YS Kim S Kummar G Giaccone JB Trepel 2008 Histone deacetylase inhibitors in cancer therapy Curr Opin Oncol 20 639 649
85. V Santini A Gozzini G Ferrari 2007 Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application Curr Drug Metab 8 383 393
86. RK Lindemann B Gabrielli RW Johnstone 2004 Histone-deacetylase inhibitors for the treatment of cancer Cell Cycle 3 779 788 (Pubitemid 40187911)
87. PA Marks VM Richon T Miller WK Kelly 2004 Histone deacetylase inhibitors Adv Cancer Res 91 137 168 (Pubitemid 39140958)
88. RR Rosato S Grant 2004 Histone deacetylase inhibitors in clinical development Expert Opin Investig Drugs 13 21 38 (Pubitemid 38111432)
89. DC Drummond CO Noble DB Kirpotin Z Guo GK Scott CC Benz 2005 Clinical development of histone deacetylase inhibitors as anticancer agents Annu Rev Pharmacol Toxicol 45 495 528 (Pubitemid 40261815)
90. WK Kelly AP Marks 2005 Drug insight: Histone deacetylase inhibitors development of the new targeted anticancer agent suberolyanilide hydroxamic acid Nat Clin Pract Oncol 2 1 8
91. PN Munster T Troso-Sandoval N Rosen 2001 The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells Cancer Res 61 8492 8497 (Pubitemid 33131130)
92. TH Luu RJ Morgan L Leong D Lim M McNamara J Portnow P Frankel DD Smith JH Doroshow DR Gandara A Aparicio G Somlo C Wong 2008 A phase ii trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study Clin Cancer Res 14 7138 7142
93. P Richardson C Mitsiades K Colson E Reilly L McBride J Chiao L Sun J Ricker S Rizvi C Oerth B Atkins I Fearen K Anderson D Siegel 2008 Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 502 507
94. M Crump B Coiffier ED Jacobsen L Sun JL Ricker H Xie SR Frankel SS Randolph BD Cheson 2008 Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B cell lymphoma Ann Oncol 19 964 969
95. SC Modesitt M Sill JS Hoffman DP Bender Gynecologic Oncology Group 2008 A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 109 182 186
96. GR Blumenschein Jr MS Kies VA Papadimitrakopoulou C Lu AJ Kumar JL Ricker JH Chiao C Chen SR Frankel 2008 Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer Invest New Drugs 26 81 87
97. SS Ramalingam RA Parise RK Ramanathan TF Lagattuta LA Musguire RG Stoller DM Potter AE Argiris JA Zwiebel MJ Egorin CP Belani 2007 Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies Clin Cancer Res 13 3605 3610 (Pubitemid 46955122)
98. J Fang Y Shing D Wiederschain L Yan C Butterfield G Jackson J Harper G Tamvakopoulos MA Moses 2000 Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model Proc Natl Acad Sci USA 97 3884 3889 (Pubitemid 30226056)
99. LM Coussens B Fingleton M Lynn 2002 Matrisian matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2387 2392 (Pubitemid 34270240)
100. Boasberg P, Harbaugh BL, Eisenberger M, Harris J, Langleben A, Ahnmann F, Roth B, Berkheimer M, Ramussen H (1997) Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. Proc Am Soc Clin Oncol 16:316a
101. J Fielding J Scholefield R Stuart R Hawkins P McCulloch T Maughan M Seymour E Van Custem C Thorlacius-Ussing C Hovendal 2000 A randomized double-blind placebo-controlled study of marimistat in patients with inoperable gastric adenocarcinoma Proc Am Soc Clin Oncol 19 240a
102. A Price Q Shi D Morris ME Wilcox PMA Brasher NB Rewcastle D Shalinsky H Zou K Appelt RN Johnston VW Yong D Edwards P Forsyth 1999 Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340 Clin Cancer Res 5 845 854 (Pubitemid 29180837)
103. O Santos CD McDermott R Daniels K Appelt 1997 Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases Clin Exp Metastasis 15 499 508 (Pubitemid 27323899)
104. D Bissett KJ O'Byrne J von Pawel U Gatzemeier A Price M Nicolson R Mercier E Mazabel C Penning MH Zhang MA Collier FA Shepherd 2005 Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer J Clin Oncol 23 842 849 (Pubitemid 46224184)
105. N Opacic M Barbaric B Zorc M Cetina A Nagl D Frkovic M Kralj K Pavelic J Balzarini G Andrei R Snoeck E De Clercq S Raic-Malic M Mintas 2005 The novel l- and d-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations J Med Chem 48 475 482 (Pubitemid 40139790)
106. I Perkovic I Butula B Zorc K Hock S Kraljevic Pavelic K Pavelic E De Clercq J Balzarini M Mintas 2008 Novel lipophilic hydroxyurea derivatives: synthesis, cytostatic and antiviral activity evaluations Chem Biol Drug Des 71 546 553
107. M Yoshida S Horinouchi T Beppu 1995 Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function BioEssays 17 423 430
108. VM Richon S Emiliani E Verdin J Webb R Breslow RA Rifkind PA Marks 1998 A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc Natl Acad Sci USA 95 3303 3307
109. LA Cohen S Amin PA Marks RA Rifkind D Desai VM Richon 1999 Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA) Anticancer Res 19 4999 5005 (Pubitemid 30103315)